| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
58,625,000 |
| Market
Cap: |
1.76(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.72 - $37.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
98,505 |
119,208 |
124,343 |
450,780 |
| Total Sell Value |
$3,345,846 |
$3,929,526 |
$4,091,741 |
$15,155,681 |
| Total People Sold |
1 |
5 |
5 |
6 |
| Total Sell Transactions |
6 |
10 |
11 |
37 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Khattar Jack A. |
President, CEO |
• • – |
2022-03-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
20,000 |
576,466 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2022-03-14 |
4/A |
OE |
$0.00 |
$0 |
D/D |
40,000 |
556,466 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
616,466 |
|
- |
|
| Gemayel Georges |
Director |
– • – |
2022-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,222 |
9,433 |
|
- |
|
| Hudson Frederick M. |
Director |
– • – |
2022-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,222 |
22,263 |
|
- |
|
| Siebert John M |
Director |
– • – |
2022-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,222 |
80,175 |
|
- |
|
| Newhall Charles W III |
Director |
– • – |
2022-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,222 |
101,731 |
|
- |
|
| Barlow Carrolee |
Director |
– • – |
2022-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,222 |
9,433 |
|
- |
|
| Siebert John M |
Director |
– • – |
2021-08-11 |
4 |
OE |
$12.98 |
$194,700 |
D/D |
15,000 |
75,953 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2021-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
556,466 |
|
- |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2021-04-14 |
4 |
AS |
$31.98 |
$99,938 |
D/D |
(3,125) |
86,326 |
|
-21% |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2021-04-14 |
4 |
OE |
$12.98 |
$40,563 |
D/D |
3,125 |
89,451 |
|
- |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2021-04-13 |
4 |
AS |
$29.98 |
$93,702 |
D/D |
(3,125) |
86,326 |
|
-23% |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2021-04-13 |
4 |
OE |
$12.98 |
$40,563 |
D/D |
3,125 |
89,451 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2021-03-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,000) |
1,058,450 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
516,466 |
|
- |
|
| Schwabe Stefan K.f. |
Executive Vice President & CMO |
• – – |
2020-12-21 |
4 |
AS |
$22.10 |
$1,024,463 |
D/D |
(46,347) |
2,772 |
|
38% |
|
| Schwabe Stefan K.f. |
Executive Vice President & CMO |
• – – |
2020-12-21 |
4 |
OE |
$12.98 |
$601,584 |
D/D |
46,347 |
49,119 |
|
- |
|
| Schwabe Stefan K.f. |
Executive Vice President & CMO |
• – – |
2020-12-14 |
4 |
AS |
$21.86 |
$1,173,264 |
D/D |
(53,653) |
2,772 |
|
47% |
|
| Schwabe Stefan K.f. |
Executive Vice President & CMO |
• – – |
2020-12-14 |
4 |
OE |
$9.13 |
$503,916 |
D/D |
53,653 |
56,425 |
|
- |
|
| Patrick Gregory S |
Sr. VP Chief Financial Officer |
• – – |
2020-11-09 |
4 |
AS |
$25.00 |
$125,000 |
D/D |
(5,000) |
44,463 |
|
9% |
|
| Patrick Gregory S |
Sr. VP Chief Financial Officer |
• – – |
2020-11-09 |
4 |
OE |
$12.98 |
$64,900 |
D/D |
5,000 |
49,463 |
|
- |
|
| Patrick Gregory S |
Sr. VP, CFO |
• – – |
2020-11-05 |
4 |
AS |
$23.00 |
$115,000 |
D/D |
(5,000) |
44,463 |
|
11% |
|
| Patrick Gregory S |
Sr. VP, CFO |
• – – |
2020-11-05 |
4 |
OE |
$12.98 |
$64,900 |
D/D |
5,000 |
49,463 |
|
- |
|
| Patrick Gregory S |
Sr. VP, CFO |
• – – |
2020-10-15 |
4 |
AS |
$20.03 |
$300,507 |
D/D |
(15,000) |
44,463 |
|
45% |
|
345 Records found
|
|
Page 7 of 14 |
|
|
0.76 (2.59%) 
